Publications by authors named "H Subrtova"

Resistance to chemotherapeutics and targeted drugs is one of the main problems in successful cancer therapy. Various mechanisms have been identified to contribute to drug resistance. One of those mechanisms is lysosome-mediated drug resistance.

View Article and Find Full Text PDF

Aim: To evaluate options of diagnostic and therapeutic procedures of sympathetic ophthalmia (SO) compared with literature data. Backgroud: SO is an ocular autoimmune disease. It is characterized by disbalance in the imunoregulatory T-subsets within cell mediated immune response.

View Article and Find Full Text PDF

Nucleoli were studied in circulating myeloblasts of myeloblastic (FAB M1, M2), promyelocytic (FAB M3) and myelomonocytic (FAB M4) acute myeloid leukemias (AMLs) using a cytochemical procedure for the demonstration of RNA. In patients untreated with cytostatic chemotherapy, myeloblasts of myeloblastic acute leukemias possessed less frequently "active large" nucleoli and more frequently "inactive" micronucleoli in comparison with other investigated types of AMLs. When myeloblasts were classified according to the presence of functionally dominant nucleoli, the higher percentage of "terminal" myeloblasts containing only micronucleoli in this type of AML was significantly reduced in patients treated with the cytostatic chemotherapy.

View Article and Find Full Text PDF

Nucleoli were studied in all stages of the granulopoietic proliferating compartment in the bone marrow of patients suffering from chronic myeloid leukemia to provide an information on the incidence of the nucleolar functional asynchrony (imbalance) in these cells. The nucleolar functional asynchrony is morphologically expressed by the presence of "active" large nucleoli with a relatively uniform distribution of ribonucleic acid (RNA) and "resting" ring shaped nucleoli with RNA only in their peripheral part in one and the same cell. This phenomenon was noted in a small but constant percentage of myeloblasts and decreased in myelocytes regardless of the phase of the disease and therapy.

View Article and Find Full Text PDF